Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
| Data | Nome del titolare | Azioni transazionate | Intervallo di valore ($) | Tipo di transazione | Intervallo di prezzo ($) | Azioni a fine dichiarazione | % di variazione |
|---|---|---|---|---|---|---|---|
| 2026-06-22 | Dr. Jula InrigExec. VP, Head of Research & Development and Chief Medical Officer | -468,00 | 0,00 | Other Disposition | - | 112,77k | -0,41% |
| 2026-06-12 | Mr. Timothy P. CoughlinIndependent Director | -10,00k | 235,55k | Derivative Exercise and Sale | 26,52 - 50,07 | 56,25k | - |
| 2026-06-12 | Dr. Roy D. BaynesIndependent Director | -4,50k | 128,79k | Derivative Exercise and Sale | 21,38 - 50,00 | 41,50k | - |
| 2026-05-15 | Mr. Timothy P. CoughlinIndependent Director | -3,25k | 141,34k | Automatic Disposition | 43,49 | 52,25k | -5,86% |
| 2026-05-04 | Dr. William E. RoteChief Research Officer | -2,76k | 121,43k | Derivative Exercise and Sale | 43,95 | 65,87k | - |
| 2026-05-04 | Dr. William E. RoteChief Research Officer | 1,49k | 0,00 | Derivative Exercise and Retained Stock | - | 65,87k | 2,31% |
| 2026-05-04 | Ms. Elizabeth E. ReedChief Legal Officer, General Counsel & Secretary | -24,25k | 733,46k | Derivative Exercise and Sale | 17,96 - 46,65 | 105,21k | - |
| 2026-05-05 | Dr. Roy D. BaynesIndependent Director | -4,50k | 127,71k | Derivative Exercise and Sale | 18,27 - 46,65 | 37,50k | - |
| 2026-05-04 | Mr. Jeffrey A. MecklerIndependent Director | -8,00k | 229,36k | Derivative Exercise and Sale | 16,33 - 45,00 | 87,50k | - |
| 2026-05-04 | Dr. Eric M. DubePresident, CEO & Director | -22,50k | 988,88k | Derivative Exercise and Sale | 43,95 | 152,37k | - |
| 2026-05-06 | Dr. Jula InrigExec. VP, Head of Research & Development and Chief Medical Officer | -311,00 | 13,67k | Automatic Disposition | 43,95 | 113,24k | -0,27% |
| 2026-05-05 | Dr. Jula InrigExec. VP, Head of Research & Development and Chief Medical Officer | -2,17k | 101,42k | Vendita | 46,65 | 113,24k | -1,88% |
| 2026-05-04 | Dr. Jula InrigExec. VP, Head of Research & Development and Chief Medical Officer | -20,00k | 452,00k | Derivative Exercise and Sale | 22,40 - 45,00 | 113,24k | - |
| 2026-05-04 | Dr. Jula InrigExec. VP, Head of Research & Development and Chief Medical Officer | 4,25k | 0,00 | Derivative Exercise and Retained Stock | - | 113,24k | 3,90% |
| 2026-05-04 | Mr. Christopher ClineCFO | -2,49k | 115,37k | Derivative Exercise and Sale | 43,95 - 46,65 | 118,66k | - |
| 2026-05-04 | Mr. Christopher ClineCFO | 1,76k | 0,00 | Derivative Exercise and Retained Stock | - | 118,66k | 1,50% |
| 2026-05-04 | Mr. Peter HeermaChief Commercial Officer | -2,17k | 101,42k | Derivative Exercise and Sale | 46,65 | 85,05k | - |
| 2026-05-04 | Mr. Peter HeermaChief Commercial Officer | 2,08k | 0,00 | Derivative Exercise and Retained Stock | - | 85,05k | 2,50% |
| 2026-05-01 | Dr. Roy D. BaynesIndependent Director | -9,75k | 364,65k | Derivative Exercise and Sale | 6,82 - 44,22 | 37,50k | - |
| 2026-04-22 | Dr. William E. RoteChief Research Officer | -9,10k | 355,72k | Automatic Disposition | 39,09 | 60,21k | -13,13% |
| 2026-04-14 | Ms. Sandra CalvinSVP, Corporate Controller & CAO | -15,25k | 381,52k | Derivative Exercise and Sale | 8,93 - 41,07 | 42,35k | - |
| 2026-04-14 | Ms. Sandra CalvinSVP, Corporate Controller & CAO | -6,73k | 276,28k | Automatic Disposition | 41,07 | 42,35k | -13,71% |
| 2026-04-14 | Dr. Roy D. BaynesIndependent Director | -32,75k | 775,82k | Derivative Exercise and Sale | 15,43 - 42,12 | 37,50k | - |
| 2026-04-14 | Mr. Gary A. LyonsIndependent Chairman of the Board | -8,00k | 197,92k | Derivative Exercise and Sale | 16,33 - 41,07 | 57,50k | - |
| 2026-04-14 | Mr. Peter HeermaChief Commercial Officer | -7,22k | 302,52k | Vendita | 41,93 | 78,80k | -8,39% |
| 2026-04-14 | Ms. Elizabeth E. ReedChief Legal Officer, General Counsel & Secretary | -37,50k | 874,18k | Derivative Exercise and Sale | 15,46 - 41,07 | 105,21k | - |
| 2026-04-14 | Ms. Elizabeth E. ReedChief Legal Officer, General Counsel & Secretary | -7,22k | 302,52k | Vendita | 41,93 | 105,21k | -6,42% |
| 2026-04-15 | Ms. Elizabeth E. ReedChief Legal Officer, General Counsel & Secretary | -6,79k | 283,81k | Automatic Disposition | 41,62 - 42,53 | 105,21k | -6,06% |
| 2026-04-15 | Dr. Eric M. DubePresident, CEO & Director | -64,00k | 2,63M | Automatic Disposition | 41,01 - 42,66 | 129,71k | -33,04% |
| 2026-04-14 | Dr. Jula InrigExec. VP, Head of Research & Development and Chief Medical Officer | -7,22k | 302,52k | Vendita | 41,93 | 111,47k | -6,08% |
| 2026-04-15 | Dr. Jula InrigExec. VP, Head of Research & Development and Chief Medical Officer | -1,02k | 43,38k | Automatic Disposition | 42,61 | 111,47k | -0,90% |
| 2026-04-13 | Mr. Christopher ClineCFO | -7,30k | 305,40k | Vendita | 28,85 - 41,93 | 116,90k | -5,88% |
| 2026-04-14 | Mr. Christopher ClineCFO | -1,02k | 43,58k | Automatic Disposition | 41,07 - 42,61 | 116,90k | -0,87% |
| 2026-04-06 | Dr. Roy D. BaynesIndependent Director | -10,00k | 64,80k | Derivative Exercise and Sale | 26,52 - 33,00 | 37,50k | - |
| 2026-04-01 | Ms. Elizabeth E. ReedChief Legal Officer, General Counsel & Secretary | -10,00k | 145,40k | Derivative Exercise and Sale | 15,46 - 30,00 | 105,21k | - |
| 2026-04-01 | Dr. Eric M. DubePresident, CEO & Director | -60,00k | 928,24k | Derivative Exercise and Sale | 15,46 - 31,46 | 129,71k | - |
| 2026-03-16 | Ms. Elizabeth E. ReedChief Legal Officer, General Counsel & Secretary | -10,00k | 90,06k | Derivative Exercise and Sale | 19,08 - 28,09 | 105,21k | - |
| 2026-02-20 | Dr. Eric M. DubePresident, CEO & Director | -60,00k | 878,17k | Derivative Exercise and Sale | 15,46 - 30,10 | 129,71k | - |
| 2026-02-17 | Ms. Elizabeth E. ReedChief Legal Officer, General Counsel & Secretary | -10,00k | 87,52k | Derivative Exercise and Sale | 19,08 - 28,26 | 105,21k | - |
| 2026-02-04 | Ms. Elizabeth E. ReedChief Legal Officer, General Counsel & Secretary | -2,99k | 96,36k | Automatic Disposition | 32,07 - 32,74 | 105,21k | -2,77% |
| 2026-02-04 | Dr. Jula InrigExec. VP, Head of Research & Development and Chief Medical Officer | -1,78k | 57,30k | Automatic Disposition | 32,11 - 32,85 | 105,71k | -1,66% |
| 2026-02-04 | Mr. Christopher ClineCFO | -1,75k | 56,17k | Automatic Disposition | 32,14 - 32,90 | 111,23k | -1,54% |
| 2026-02-03 | Ms. Sandra CalvinSVP, Corporate Controller & CAO | -4,33k | 139,18k | Vendita | 32,12 | 49,08k | -8,11% |
| 2026-02-03 | Ms. Elizabeth E. ReedChief Legal Officer, General Counsel & Secretary | -7,18k | 230,46k | Vendita | 32,12 | 108,21k | -6,22% |
| 2026-02-03 | Dr. William E. RoteChief Research Officer | -12,45k | 409,10k | Automatic Disposition | 32,87 | 55,31k | -18,37% |
| 2026-02-03 | Dr. Eric M. DubePresident, CEO & Director | -100,09k | 3,23M | Automatic Disposition | 32,06 - 32,70 | 129,71k | -43,55% |
| 2026-02-03 | Dr. Jula InrigExec. VP, Head of Research & Development and Chief Medical Officer | -6,96k | 223,43k | Vendita | 32,12 | 107,49k | -6,08% |
| 2026-02-03 | Mr. Christopher ClineCFO | -7,24k | 232,61k | Vendita | 32,12 | 112,97k | -6,02% |
| 2026-02-03 | Mr. Peter HeermaChief Commercial Officer | -7,31k | 234,80k | Vendita | 32,12 | 72,02k | -9,22% |
| 2026-01-23 | Dr. Eric M. DubePresident, CEO & Director | -60,00k | 877,53k | Derivative Exercise and Sale | 15,46 - 30,10 | 129,71k | - |
| 2026-01-20 | Ms. Elizabeth E. ReedChief Legal Officer, General Counsel & Secretary | -10,00k | 82,62k | Derivative Exercise and Sale | 19,08 - 27,34 | 90,27k | - |
| 2026-01-05 | Dr. Jula InrigExec. VP, Head of Research & Development and Chief Medical Officer | -2,03k | 81,61k | Vendita | 40,18 | 86,31k | -2,30% |
| 2026-01-06 | Dr. Jula InrigExec. VP, Head of Research & Development and Chief Medical Officer | -445,00 | 16,80k | Automatic Disposition | 37,75 | 86,31k | -0,51% |
| 2025-12-24 | Mr. Peter HeermaChief Commercial Officer | -4,98k | 199,20k | Automatic Disposition | 40,00 | 65,64k | -7,05% |
| 2025-12-24 | Dr. William E. RoteChief Research Officer | -60,00k | 1,17M | Derivative Exercise and Sale | 20,61 - 40,10 | 48,61k | - |
| 2025-12-24 | Dr. Jula InrigExec. VP, Head of Research & Development and Chief Medical Officer | -15,00k | 496,05k | Derivative Exercise and Sale | 8,93 - 42,00 | 88,79k | - |
| 2025-12-24 | Ms. Sandra CalvinSVP, Corporate Controller & CAO | -7,40k | 296,08k | Automatic Disposition | 40,00 | 38,23k | -16,22% |
| 2025-12-15 | Ms. Sandra CalvinSVP, Corporate Controller & CAO | -2,91k | 104,76k | Automatic Disposition | 36,00 | 45,64k | -5,99% |
| 2025-12-01 | Mr. Christopher ClineCFO | -20,00k | 375,60k | Derivative Exercise and Sale | 16,23 - 35,01 | 92,08k | - |
| 2025-11-04 | Ms. Sandra CalvinSVP, Corporate Controller & CAO | -61,25k | 733,79k | Derivative Exercise and Sale | 8,93 - 36,00 | 48,55k | - |
| 2025-11-04 | Ms. Sandra CalvinSVP, Corporate Controller & CAO | -5,87k | 211,14k | Automatic Disposition | 36,00 | 48,55k | -10,78% |
| 2025-10-31 | Mr. Timothy P. CoughlinIndependent Director | -18,00k | 325,56k | Derivative Exercise and Sale | 16,33 - 35,03 | 55,50k | - |
| 2025-10-31 | Mr. Peter HeermaChief Commercial Officer | -5,59k | 195,69k | Automatic Disposition | 35,00 | 70,62k | -7,34% |
| 2025-11-03 | Mr. Peter HeermaChief Commercial Officer | -1,08k | 0,00 | Other Disposition | - | 70,62k | -1,50% |
| 2025-10-28 | Dr. Eric M. DubePresident, CEO & Director | -120,00k | 1,78M | Derivative Exercise and Sale | 15,46 - 30,38 | 129,71k | - |
| 2025-10-28 | Mr. Peter HeermaChief Commercial Officer | -2,66k | 79,86k | Automatic Disposition | 30,00 | 77,29k | -3,33% |
| 2025-09-22 | Ms. Elizabeth E. ReedChief Legal Officer, General Counsel & Secretary | -10,00k | 59,20k | Derivative Exercise and Sale | 19,08 - 25,00 | 89,88k | - |
| 2025-09-23 | Mr. Peter HeermaChief Commercial Officer | -891,00 | 0,00 | Other Disposition | - | 79,95k | -1,10% |
| 2025-09-03 | Mr. Christopher ClineCFO | -454,00 | 8,26k | Vendita | 18,20 | 92,08k | -0,49% |
| 2025-09-04 | Mr. Christopher ClineCFO | -119,00 | 2,35k | Automatic Disposition | 19,71 | 92,08k | -0,13% |
| 2025-08-27 | Mr. Christopher ClineCFO | -470,00 | 8,14k | Automatic Disposition | 17,31 | 92,66k | -0,50% |
Le azioni che visualizzerai appariranno in questo riquadro, così potrai facilmente tornare alle quotazioni di tuo interesse.
Assistenza: support@advfn.it
Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni
Registrati con e-mail
Hai già un account? Accedi
Non hai un account? Registrati
Registrandomi, confermo di aver letto, capito, e accetto i termini e condizioni ADVFN e che sono un investitore privato.
Caratteristiche principali
Premium
